Shionogi closes $2 billion IntraBio deal, adds AQNEURSA
Shionogi closed its $2 billion IntraBio acquisition, gaining worldwide AQNEURSA rights, U.S. and European Niemann-Pick approvals, and a platform to expand rare-disease treatments.
Topic
Topic
Shionogi closed its $2 billion IntraBio acquisition, gaining worldwide AQNEURSA rights, U.S. and European Niemann-Pick approvals, and a platform to expand rare-disease treatments.